Optibiotix Health Plc (OPTI) is a York, the United Kingdom-based life sciences company, engaged in the research and development into microbiome modulators. The company identifies and develops a range of products to modify the human microbiome. The group has established a pipeline of microbiome modulators, while this can impact on the energy harvest, appetite suppression, and lipid and cholesterol management. The company’s three core screening platform are OptiScreen, OptiBiome, and OptiBiotics.
Financial Highlights (FY2018, £)
(Source: Annual Report, Company Website)
The company’s reported revenue increased from £191 thousand in 2017 to £514 thousand in 2018. Most of this income (£434 thousand) was generated in H2 FY18 (June to November 30, 2018). The operating loss stood at £1,499 thousand, which was £628 thousand lower than the same period of last year data of (£2,127) thousand. In FY2018, the loss for the period stood at £1,893 thousand. Basic loss per share from continued operations was 2.33 pence, a significant decrease from the last year profit per share of 2.43 pence. At November 30, 2018, the Company had cash in the bank of £1.33 million.
The Board recognises the importance of KPIs in driving appropriate behaviour and enabling of Group’s performance. For the year to 30 November 2018, the primary KPI’s were the completion of commercial agreements and the expansion of the Optibiotic platform. The Group intends to review the following non-financial KPIs going forward - Customer relationships, IP and trademark registrations, Service quality and brand awareness, and Attraction, motivation and retention of employees.
The company had announced the appointment of Stephen Prescott as Chief Executive Officer (CEO) of its wholly owned subsidiary, ProBiotix Health Ltd. ProBiotix was created to develop science-based healthy bacteria called probiotics to reduce cardiovascular risk.
Share Price Performance
Daily Chart as at May-30-19, after the market closed (Source: Thomson Reuters)
On May 30, 2019, OPTI shares closed at GBX 87.5 and remained flat against the previous day closing price. Stock's 52 weeks High and Low is GBX 133.25/GBX 60. At the time of writing, the share was trading 34.33 per cent lower than the 52w High and 45.83 per cent higher than the 52w low.
Stock's average traded volume for 5 days was 110,080.80; 30 days - 165,913.70 and 90 days – 173,479.64. The average traded volume for 5 days was down by 33.65 per cent as compared to 30 days average traded volume. The outstanding market capitalisation was around £74.87 million.
In 2019, the company anticipates further revenue progress, due to the current deals which will contribute to the full-year revenue progress. The group will invest in its clinical and scientific studies. The current consensus is that Brexit will not affect the regulations that are relevant to the business.
The company has achieved several scientific awards for the science at ProBiota and wonweight Management of the Year fro SlimBiome at Viafoods 2018.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.